Phaseline

Targets › ENG

ENG (Endoglin): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 5 Phase 2, 3 Phase 1; Oncology; next expected readout Apr 2027.

Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis. Required for normal structure and integrity of adult vasculature. (UniProt, P17813)

Open in Phaseline: the race on ENG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of WashingtonCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX
ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1Phase 2Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast CarcinomaApr 2027
Edwin Posadas, MDCarotuximab
Endoglin inhibitor
ENGPhase 2Castration-resistant Prostate CancerJan 2028
Karen Reckamp, MD, MSCarotuximab
Endoglin inhibitor
ENGPhase 1Non Small Cell Lung CancerJan 2028
West China HospitalEDS01
Recombinant human endostatin adenovirus vector
ENGPhase 1Head & Neck CancerMar 2028

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 (2) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1) Castration-resistant Prostate Cancer (1) Head & Neck Cancer (1) Non Small Cell Lung Cancer (1)

Modalities

mixed (3), antibody (1)

Companies

University of Washington (1) Edwin Posadas, MD (1) West China Hospital (1) Karen Reckamp, MD, MS (1)

Related targets

YBX1 (1) SOX2 (1) CDH3 (1) MDM2 (1) CD105 (1) YB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.